Natco Pharma Q1 Profit Slumps 22% on US Pricing Pressure 📌

• Natco Pharma Ltd posted a 22.1% year-on-year (YoY) drop in consolidated net profit for Q1FY26, coming in at ₹480 crore compared to ₹668.5 crore in the same period last year. The decline was primarily driven by pricing pressure in its US portfolio and a rise in R\&D spending.Revenue from operations slipped 2.5% YoY to ₹1,329 crore, while EBITDA declined 32% to ₹519 crore from ₹764.9 crore a year earlier.Operating margins narrowed significantly to 39% from 56.1% in the previous year, as the company ramped up investments in high-value research initiatives.